{"id":7617,"date":"2020-07-15T13:50:10","date_gmt":"2020-07-15T13:50:10","guid":{"rendered":"https:\/\/zuviuslifesciences.in\/old\/?post_type=product&p=7617"},"modified":"2020-07-20T15:51:43","modified_gmt":"2020-07-20T15:51:43","slug":"aspraginaz-inj","status":"publish","type":"product","link":"https:\/\/zuviuslifesciences.in\/old\/product\/aspraginaz-inj\/","title":{"rendered":"Aspraginaz Inj"},"content":{"rendered":"

[vc_row][vc_column][vc_tta_tour color=”peacoc” active_section=”1″][vc_tta_section title=”Description” tab_id=”1584624217032-a15849ed-97bb”][vc_column_text]ASPRAGINAZ <\/b>(L-Asparaginase) contains L-Asparagine amidohydrolase, type EC-2, an enzyme derived from Escherichia coll. The activity of <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) is expressed in terms of International Units according to the recommendation of the International Union of Biochemistry. The definition of one International Unit of L-Asparaginase is the amount of enzyme required to generate 1 <\/span>\u03bcmol<\/span> of ammonia per minute at pH 7.3 and 37<\/span>\u00b0<\/span>C. The specific activity of <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) is at least 225 International Units per milligram of protein. It is a monomer thought to consist of four subunits of molecular weight about 33,000 each, for a unit molecular weight of 133,000 \u00b1 5,000.<\/span>[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Composition” tab_id=”1593256673750-3638ffc1-7c86″][vc_column_text]ASPRAGINAZ 5000<\/b><\/p>\n

Each vial contains:
\n<\/span>L-Asparaginase \u2026\u2026\u2026\u2026..5000 I.U.
\n<\/span>Glycine IP\u2026\u2026\u2026\u2026\u2026\u2026\u2026…q.s.
\n<\/span>Water for Injection IP\u2026\u2026\u2026…q.s.<\/span><\/p>\n

ASPRAGINAZ 10000<\/b><\/p>\n

Each vial contains:
\n<\/span>L-Asparaginase \u2026\u2026\u2026\u2026..10000 I.U.
\n<\/span>Glycine IP\u2026\u2026\u2026\u2026\u2026\u2026 \u00a0 …q.s.
\n<\/span>Water for Injection IP\u2026\u2026\u2026…q.s.
\n<\/span><\/p>\n

DOSAGE FORM
\n<\/b>Lyophilized Powder for Injection.<\/span><\/p>\n

\u00a0<\/span>[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Indications” tab_id=”1584624839401-59481bbb-bdc7″][vc_column_text]ASPRAGINAZ <\/b>(L-Asparaginase) is indicated in the therapy of patients with acute lymphocytic leukemia. This agent is useful primarily in combination with other chemotherapeutic agents in the induction of remissions of the disease in pediatric patients.<\/span><\/p>\n

ASPRAGINAZ <\/b>(L-Asparaginase) should not be used as the sole induction agent unless combination therapy is deemed inappropriate.<\/span><\/p>\n

ASPRAGINAZ <\/b>(L-Asparaginase) is not recommended for maintenance therapy.<\/span>[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Dosage & Administration” tab_id=”1584625017135-3ffdd9c5-1bd6″][vc_column_text]This drug may have toxic properties and must be handled and administered with care Special handling procedures should be reviewed prior to handling and followed diligently during reconstitution and administration. Inhalation of dust or aerosols and contact with skin or mucous membranes, especially those of the eyes, must be avoided. <\/span>(See DOSAGE AND METHOD OF ADMINISTRATION, <\/b>Special Handling).<\/span><\/i><\/p>\n

As a component of selected multiple agent induction regimens, <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) may be administered by either the intravenous or the intramuscular route. When administered intravenously this enzyme should be given over a period of not less than thirty minutes through the side arm of an already running infusion of Sodium Chloride Injection or Dextrose Injection<\/span> 5%.<\/span> ASPRAGINAZ <\/b>(L-Asparaginase) has lithe tendency to cause phlebitis when given intravenously. Anaphylactic reactions require the immediate use of epinephrine, oxygen, and intravenous steroids.<\/span><\/p>\n

When administering <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) intramuscularly, the volume at a single injection site should be limited to 2 ml. If a volume greater than 2 ml is to be administered, two injection sites should be used. Unfavorable interactions of <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) with some antitumor agents have been demonstrated. It is recommended therefore, that <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) be used in combination regimens only by physicians familiar with the benefits and risks of given regimen. During the period of its inhibition of protein synthesis and cell replication, Unfavorable interactions of <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) may interfere all the action of drugs such as methotrexate which require cell replication for their lethal effect <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) may interfere with the enzymatic detoxification of other drugs, particularly in the liver.<\/span><\/p>\n

Recommended Induction Regimens: <\/b>When using chemotherapeutic agents in combination for the induction of remissions in patients with acute lymphocytic leukemia, regimens are sought which provide maximum chance of success while avoiding excessive cumulative toxicity or negative drug interactions.<\/span><\/p>\n

One of the following combination regimens incorporating <\/span>ASPRAGINAZ <\/b>(L-Asparaginase) is recommended for acute lymphocytic leukemia in pediatric patients.<\/span><\/p>\n

In the Regimens below, Day 1 is considered to be the first day of therapy.<\/span><\/p>\n

Regimen I<\/b><\/p>\n

 <\/p>\n